New York and Delaware rulings blocked Better's poison pill defenses and kept Vishal Garg's proxy campaign alive, though only at the temporary restraining order stage, following interim CEO Daniel Lewis's letter urging shareholders to reject Garg's proposals.
ReadingOperators controlling boards through defensive tactics are finding those tactics increasingly fragile. Shareholder advocacy is now filtered through judicial review before it even reaches the vote.
WatchThe next regulatory filing from Better will reveal whether Garg has secured sufficient proxy commitments to justify advancing to the shareholder meeting. If the campaign stalls, institutional support was conditional.